Clindamycin phosphate

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1972

www.ebi.ac.uk

First approval year: 1972
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Clindamycin phosphate
www.ebi.ac.uk

Molecular weight: 504.97
www.ebi.ac.uk

Structure (SMILES): CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1
www.ebi.ac.uk

cleocin
Cleocin
cleocin phosphate
Cleocin phosphate
cleocin t
Cleocin t
clinadac
Clinadac
clinda derm
Clinda-derm
clindac
Clindac
clindagel
Clindagel
clindamycin phosphate
Clindamycin phosphate
clindamycin phosphate component of acanya
Clindamycin phosphate component of acanya
clindamycin phosphate component of benzaclin
Clindamycin phosphate component of benzaclin
clindamycin phosphate component of cabtreo
Clindamycin phosphate component of cabtreo
clindamycin phosphate component of duac
Clindamycin phosphate component of duac
clindamycin phosphate component of idp 126

And 25 more, listed on the interactive page.

7 s chloro 7 deoxylincomycin 2 phosphate
7(S)-CHLORO-7-DEOXYLINCOMYCIN 2-PHOSPHATE
acanya component clindamycin phosphate
ACANYA COMPONENT CLINDAMYCIN PHOSPHATE
benzaclin component clindamycin phosphate
BENZACLIN COMPONENT CLINDAMYCIN PHOSPHATE
cabtreo component clindamycin phosphate
CABTREO COMPONENT CLINDAMYCIN PHOSPHATE
CLINDAMYCIN (AS PHOSPHATE)
clindamycin 2 dihydrogen phosphate
clindamycin 2 dihydrogen phosphate mi
clindamycin 2 phosphate
Clindamycin 2-dihydrogen phosphate
CLINDAMYCIN 2-DIHYDROGEN PHOSPHATE [MI]
CLINDAMYCIN 2-PHOSPHATE
clindamycin as phosphate
clindamycin phosphate
Clindamycin phosphate
CLINDAMYCIN PHOSPHATE [EP MONOGRAPH]
CLINDAMYCIN PHOSPHATE [JAN]
CLINDAMYCIN PHOSPHATE [MART.]
CLINDAMYCIN PHOSPHATE [ORANGE BOOK]
CLINDAMYCIN PHOSPHATE [USAN]
CLINDAMYCIN PHOSPHATE [USP MONOGRAPH]
CLINDAMYCIN PHOSPHATE [USP-RS]

And 43 more, listed on the interactive page.

CAS registry numbers

24729-96-2

ChEMBL ID: CHEMBL3184512
www.ebi.ac.uk

InChIKey: UFUVLHLTWXBHGZ-MGZQPHGTSA-N
www.ebi.ac.uk

PubChem compound IDs

443385

FDA ingredient codes (UNII)

EH6D7113I8

21235
797272

Applicant: PFIZER
Approval date: 2 Oct 1972
Application number: NDA050441

Patents: 3
Designations: 0
Earliest recorded loss of exclusivity: 22 Sept 2036
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only
Boxed warning: Yes

Drug name stem: -mycin

Administration routes

Parenteral
topical

Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P02358
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P02359
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P02413
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7J3
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7J7
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7K2
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7K6
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7L0
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7L3
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7L8
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7M2
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7M6
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7M9
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7N1
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7N4
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7N9
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7P5
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7Q1
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7Q6
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7R5
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7R9
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7S3
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7S9
Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome
Protein identifier
P0A7T3

And 31 more, listed on the interactive page.

Open Targets mechanisms

Mechanism
Bacterial 70S ribosome inhibitor
Action type
Inhibitor
Target
Bacterial 70S ribosome

Condition
Soft Tissue Infections
Highest recorded phase
4
Subject identifier
D018461
Condition
Infections
Highest recorded phase
4
Condition identifier
EFO:0000544
Subject identifier
D007239
Condition
Intraabdominal Infections
Highest recorded phase
4
Condition identifier
EFO:0000544
Subject identifier
D059413
Condition
Irritable Bowel Syndrome
Highest recorded phase
4
Condition identifier
EFO:0000555
Subject identifier
D043183
Condition
Abscess
Highest recorded phase
4
Condition identifier
EFO:0003030
Subject identifier
D000038
Condition
Empyema
Highest recorded phase
4
Condition identifier
EFO:0003097
Subject identifier
D004653
Condition
Osteomyelitis
Highest recorded phase
4
Condition identifier
EFO:0003102
Subject identifier
D010019
Condition
Pneumonia
Highest recorded phase
4
Condition identifier
EFO:0003106
Subject identifier
D011014
Condition
Acne Vulgaris
Highest recorded phase
4
Condition identifier
EFO:0003894
Subject identifier
D000152
Condition
Vaginosis, Bacterial
Highest recorded phase
4
Condition identifier
EFO:0003932
Subject identifier
D016585
Condition
Peritonitis
Highest recorded phase
4
Condition identifier
EFO:0008588
Subject identifier
D010538
Condition
Genital Diseases, Female
Highest recorded phase
4
Condition identifier
EFO:0009549
Subject identifier
D005831
Condition
Rosacea
Highest recorded phase
2
Condition identifier
EFO:1000760
Subject identifier
D012393
Condition
Parametritis
Highest recorded phase
4
Condition identifier
EFO:1001084
Subject identifier
D010249
Condition
Vulvovaginitis
Highest recorded phase
3
Condition identifier
EFO:1001240
Subject identifier
D014848
Condition
Endometritis
Highest recorded phase
4
Condition identifier
EFO:1001312
Subject identifier
D004716
Condition
Enterocolitis, Pseudomembranous
Highest recorded phase
4
Condition identifier
EFO:1001314
Subject identifier
D004761
Condition
Lung Abscess
Highest recorded phase
4
Condition identifier
EFO:1001362
Subject identifier
D008169
Condition
Abdominal Abscess
Highest recorded phase
4
Condition identifier
EFO:1001753
Subject identifier
D018784
Condition
Sepsis
Highest recorded phase
4
Condition identifier
HP:0100806
Subject identifier
D018805
Condition
Vaginitis
Highest recorded phase
3
Condition identifier
MONDO:0002234
Subject identifier
D014627
Condition
Respiratory Tract Infections
Highest recorded phase
4
Condition identifier
MONDO:0024355
Subject identifier
D012141

Condition identifier
EFO_0000544
Condition identifier
EFO_0000544
Highest recorded phase
4
Condition identifier
EFO_0000555
Condition identifier
EFO_0003030
Condition identifier
EFO_0003097
Condition identifier
EFO_0003102
Condition identifier
EFO_0003106
Condition identifier
EFO_0003894
Condition identifier
EFO_0003932
Condition identifier
EFO_0008588
Condition identifier
EFO_0009549
Condition identifier
EFO_1000760
Condition identifier
EFO_1001084
Condition identifier
EFO_1001240
Highest recorded phase
3
Condition identifier
EFO_1001312
Condition identifier
EFO_1001314
Condition identifier
EFO_1001314
Highest recorded phase
4
Condition identifier
EFO_1001362
Condition identifier
EFO_1001753
Condition identifier
EFO_1001753
Highest recorded phase
4
Condition identifier
HP_0100806
Condition identifier
HP_0100806
Highest recorded phase
4
Condition identifier
MONDO_0000744
Highest recorded phase
4
Condition identifier
MONDO_0000918
Highest recorded phase
4
Condition identifier
MONDO_0002234
Highest recorded phase
3

And 14 more, listed on the interactive page.

Warning
Black Box Warning
Effect
gastrointestinal toxicity
Warning
Black Box Warning
Effect
infectious disease

Warning
Black Box Warning
Effect
gastrointestinal toxicity
Country
United States
Warning
Black Box Warning
Effect
infectious disease
Country
United States

Event
acute generalised exanthematous pustulosis
Reports
199
Reporting signal score
519.205
Event
acute kidney injury
Reports
201
Reporting signal score
84.8801
Event
clostridium difficile colitis
Reports
101
Reporting signal score
201.491
Event
clostridium difficile infection
Reports
129
Reporting signal score
235.355
Event
dermatitis allergic
Reports
104
Reporting signal score
200.904
Event
drug hypersensitivity
Reports
1,769
Reporting signal score
3,466.52
Event
drug reaction with eosinophilia and systemic symptoms
Reports
145
Reporting signal score
188.853
Event
graft infection
Reports
33
Reporting signal score
138.071
Event
oesophageal ulcer
Reports
44
Reporting signal score
90.7761
Event
pseudomembranous colitis
Reports
42
Reporting signal score
107.061
Event
rash
Reports
461
Reporting signal score
177.567
Event
rash maculo-papular
Reports
226
Reporting signal score
417.496
Event
toxic skin eruption
Reports
82
Reporting signal score
130.721
Event
type iv hypersensitivity reaction
Reports
99
Reporting signal score
298.382
Event
urticaria
Reports
213
Reporting signal score
97.7151

NCT00361322
clinicaltrials.gov
NCT00757523
clinicaltrials.gov
NCT00807014
clinicaltrials.gov
NCT00841776
clinicaltrials.gov
NCT01015638
clinicaltrials.gov
NCT01016977
clinicaltrials.gov
NCT01047189
clinicaltrials.gov
NCT01111994
clinicaltrials.gov
NCT01422785
clinicaltrials.gov
NCT01448733
clinicaltrials.gov
NCT01769235
clinicaltrials.gov
NCT01788384
clinicaltrials.gov
NCT01796665
clinicaltrials.gov
NCT01915732
clinicaltrials.gov
NCT02005666
clinicaltrials.gov
NCT03717506
clinicaltrials.gov
NCT04321070
clinicaltrials.gov
NCT05582434
clinicaltrials.gov
NCT00616330
clinicaltrials.gov
NCT00823901
clinicaltrials.gov
NCT02099240
clinicaltrials.gov
NCT03476941
clinicaltrials.gov
NCT04370548
clinicaltrials.gov

Dose: 1%
Route: Topical
How often: Twice daily

Conditions of use

Keep container tightly closed

Hydrogen bond acceptors: 8
Hydrogen bond donors: 5
Polar surface area: 148.79
Calculated partition coefficient (ALogP): 0.51
Calculated partition coefficient (XLogP): -1.2
Prodrug: Yes
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 1
Rotatable bonds: 9
Heavy atoms: 31
Molecular formula: C18H34ClN2O8PS
Monoisotopic mass: 504.1462019
Natural product: Yes

0009-0775
0009-0870
0009-0902
0009-3051
0009-3329
0009-3448
0009-4073
0009-5095
0009-7667
0168-0201
0168-0202
0168-0203
0168-0277
0187-0006
0187-3050
0338-3410
0338-3612
0338-3616
0338-3814
0338-4114
0338-9545
0338-9549
0338-9553
0404-9837
0404-9838

And 107 more, listed on the interactive page.

Recorded assays: 317
Active assays: 0

Anti-Bacterial Agents
id.nlm.nih.gov

Related records

Trials (27)

A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris
Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris
Antibiotic Irrigations for Intra-Abdominal Drains
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
Efficacy & Safety of Clindamycin and Tretinoin in Acne
Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris
Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris
Experience With Topical Acne Treatment
Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea
Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris

Approved for (14)

Abscess
Acne
Bacterial vaginosis
Clostridium difficile colitis
Empyema
Endometritis
Female reproductive system disorder
Infectious peritonitis
Irritable bowel syndrome
Lung abscess
Osteomyelitis
Parametritis
Pneumonia
Respiratory tract infectious disorder

In development for (3)

Rosacea Phase 2
Vaginitis Phase 3
Vulvovaginitis Phase 3

Clindamycin phosphate

Development status

Names and chemistry

Brand names (50)

Other names (68)

Identifiers

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (56)

Open Targets mechanisms

Investigated indications (22)

Open Targets indications (39)

Warnings (2)

Open Targets warnings (2)

Reported adverse events (15)

Trial references (23)

Dosing

Conditions of use

Chemical properties

National Drug Codes

Evidence counts

Pharmacologic actions

Related records

Trials (27)

Approved for (14)

In development for (3)